Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum.
Biomarkers
HFpEF
HFrEF
Heart failure
Proteomics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 06 2024
27 06 2024
Historique:
received:
21
03
2024
accepted:
23
06
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Circulating proteins may provide insights into the varying biological mechanisms involved in heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). We aimed to identify specific proteomic patterns for HF, by comparing proteomic profiles across the ejection fraction spectrum. We investigated 4210 circulating proteins in 739 patients with normal (Stage A/Healthy) or elevated (Stage B) filling pressures, HFpEF, or ischemic HFrEF (iHFrEF). We found 2122 differentially expressed proteins between iHFrEF-Stage A/Healthy, 1462 between iHFrEF-HFpEF and 52 between HFpEF-Stage A/Healthy. Of these 52 proteins, 50 were also found in iHFrEF vs. Stage A/Healthy, leaving SLITRK6 and NELL2 expressed in lower levels only in HFpEF. Moreover, 108 proteins, linked to regulation of cell fate commitment, differed only between iHFrEF-HFpEF. Proteomics across the HF spectrum reveals overlap in differentially expressed proteins compared to stage A/Healthy. Multiple proteins are unique for distinguishing iHFrEF from HFpEF, supporting the capacity of proteomics to discern between these conditions.
Identifiants
pubmed: 38937570
doi: 10.1038/s41598-024-65667-0
pii: 10.1038/s41598-024-65667-0
doi:
Substances chimiques
Proteome
0
Biomarkers
0
Blood Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14871Informations de copyright
© 2024. The Author(s).
Références
McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev. Esp. Cardiol. 75(6), 523 (2022).
pubmed: 35636830
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79(17), e263–e421 (2022).
pubmed: 35379503
doi: 10.1016/j.jacc.2021.12.012
Li, P. et al. Similarities and differences between HFmrEF and HFpEF. Front. Cardiovasc. Med. 8, 678614 (2021).
pubmed: 34616777
pmcid: 8488158
doi: 10.3389/fcvm.2021.678614
Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: A SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE. 6(10), e26332 (2011).
pubmed: 22022604
pmcid: 3195687
doi: 10.1371/journal.pone.0026332
Peters, A. E. et al. Proteomic pathways across ejection fraction spectrum in heart failure: An EXSCEL substudy. MedRxiv. (2023).
Adamo, L. et al. Proteomic signatures of heart failure in relation to left ventricular ejection fraction. J. Am. Coll. Cardiol. 76(17), 1982–1994 (2020).
pubmed: 33092734
pmcid: 7584807
doi: 10.1016/j.jacc.2020.08.061
Carithers, L. J. et al. A novel approach to high-quality postmortem tissue procurement: The GTEx project. Biopreserv. Biobank. 13(5), 311–319 (2015).
pubmed: 26484571
pmcid: 4675181
doi: 10.1089/bio.2015.0032
Zannad, F. et al. Effect of empagliflozin on circulating proteomics in heart failure: Mechanistic insights into the EMPEROR programme. Eur. Heart J. 43(48), 4991–5002 (2022).
pubmed: 36017745
pmcid: 9769969
doi: 10.1093/eurheartj/ehac495
Rezar, R. et al. Heart-type fatty acid-binding protein (H-FABP) and its role as a biomarker in heart failure: What do we know so far?. J. Clin. Med. 9(1), 1–164 (2020).
doi: 10.3390/jcm9010164
Carrasco-Sanchez, F. J. et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J. Card. Fail. 17(1), 31–38 (2011).
pubmed: 21187262
doi: 10.1016/j.cardfail.2010.07.248
Makki, N., Thiel, K. W. & Miller, F. J. Jr. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 14(10), 20597–20613 (2013).
pubmed: 24132149
pmcid: 3821633
doi: 10.3390/ijms141020597
Kachanova, O., Lobov, A. & Malashicheva, A. The role of the notch signaling pathway in recovery of cardiac function after myocardial infarction. Int. J. Mol. Sci. 23(20), 12509 (2022).
pubmed: 36293363
pmcid: 9604421
doi: 10.3390/ijms232012509
Sojoodi, M. et al. Peroxidasin deficiency re-programs macrophages toward pro-fibrolysis function and promotes collagen resolution in liver. Cell. Mol. Gastroenterol. Hepatol. 13(5), 1483–1509 (2022).
pubmed: 35093588
pmcid: 9043497
doi: 10.1016/j.jcmgh.2022.01.015
Wang, S., Chi, K., Wu, D. & Hong, Q. Insulin-like growth factor binding proteins in kidney disease. Front. Pharmacol. 12, 807119 (2021).
pubmed: 35002740
pmcid: 8728008
doi: 10.3389/fphar.2021.807119
Benoit, S. W., Ciccia, E. A. & Devarajan, P. Cystatin C as a biomarker of chronic kidney disease: Latest developments. Expert Rev. Mol. Diagn. 20(10), 1019–1026 (2020).
pubmed: 32450046
pmcid: 7657956
doi: 10.1080/14737159.2020.1768849
Zhang, Y. et al. Advances in understanding the effects of erythropoietin on renal fibrosis. Front. Med. 7, 47 (2020).
doi: 10.3389/fmed.2020.00047
Hoeflich, A., David, R. & Hjortebjerg, R. Current IGFBP-related biomarker research in cardiovascular disease-we need more structural and functional information in clinical studies. Front. Endocrinol. 9, 388 (2018).
doi: 10.3389/fendo.2018.00388
Maghsoudloo, M., Azimzadeh Jamalkandi, S., Najafi, A. & Masoudi-Nejad, A. Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis. Mol. Med. 26(1), 9 (2020).
pubmed: 31952466
pmcid: 6969427
doi: 10.1186/s10020-019-0135-9
McDonald, J., Bayrak-Toydemir, P. & Pyeritz, R. E. Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis. Genet. Med. 13(7), 607–616 (2011).
pubmed: 21546842
doi: 10.1097/GIM.0b013e3182136d32
Lee, W. S. & Kim, J. Insulin-like growth factor-1 signaling in cardiac aging. Biochim. Biophys. Acta Mol. Basis Dis. 1864(5 Pt B), 1931–1938 (2018).
pubmed: 28847512
doi: 10.1016/j.bbadis.2017.08.029
Guo, S. et al. The value of IGF-1 and IGFBP-1 in patients with heart failure with reduced, mid-range, and preserved ejection fraction. Front. Cardiovasc. Med. 8, 772105 (2021).
pubmed: 35127852
doi: 10.3389/fcvm.2021.772105
Haddad, F. et al. Insulin Growth factor phenotypes in heart failure with preserved ejection fraction, an INSPIRE registry and CATHGEN study. J. Card. Fail. 28(6), 935–946 (2022).
pubmed: 34979242
doi: 10.1016/j.cardfail.2021.12.012
Van Tassell, B. W., Toldo, S., Mezzaroma, E. & Abbate, A. Targeting interleukin-1 in heart disease. Circulation. 128(17), 1910–1923 (2013).
pubmed: 24146121
pmcid: 3938092
doi: 10.1161/CIRCULATIONAHA.113.003199
Buckley, L. F. & Abbate, A. Interleukin-1 blockade in cardiovascular diseases: A clinical update. Eur. Heart J. 39(22), 2063–2069 (2018).
pubmed: 29584915
doi: 10.1093/eurheartj/ehy128
Van Tassell, B. W. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure Anakinra response Trial 2 (D-HART2). Clin. Cardiol. 40(9), 626–632 (2017).
pubmed: 28475816
pmcid: 5744484
doi: 10.1002/clc.22719
Mostafaei, S. et al. Identification of novel genes in human airway epithelial cells associated with chronic obstructive pulmonary disease (COPD) using machine-based learning algorithms. Sci. Rep. 8(1), 15775 (2018).
pubmed: 30361509
pmcid: 6202402
doi: 10.1038/s41598-018-33986-8
Vedin, O. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: A nationwide cohort study. Circ. Heart Fail. 10(6), 3875 (2017).
doi: 10.1161/CIRCHEARTFAILURE.117.003875
Toma, M. et al. Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Heart Fail. 4(3), 301–311 (2017).
pubmed: 28772032
pmcid: 5542716
doi: 10.1002/ehf2.12136
Li, D., Lin, H. & Li, L. Multiple feature selection strategies identified novel cardiac gene expression signature for heart failure. Front. Physiol. 11, 604241 (2020).
pubmed: 33304275
pmcid: 7693561
doi: 10.3389/fphys.2020.604241
Jonas, A. et al. Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. J. Clin. Invest. 124(11), 5042–5056 (2014).
pubmed: 25329699
pmcid: 4347228
doi: 10.1172/JCI71385
Lopez, Y., Nakai, K. & Patil, A. HitPredict version 4: Comprehensive reliability scoring of physical protein–protein interactions from more than 100 species. Database 2015, 117 (2015).
doi: 10.1093/database/bav117
Halvorsen, B. et al. Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages. Atherosclerosis. 243(1), 204–210 (2015).
pubmed: 26402139
doi: 10.1016/j.atherosclerosis.2015.09.010
Kumar, S. et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br. J. Haematol. 74(1), 82–85 (1990).
pubmed: 2310700
doi: 10.1111/j.1365-2141.1990.00122.x-i1
Baccouche, B. M. & Rhodenhiser, E. Galectin-3 and HFpEF: Clarifying an emerging relationship. Curr. Cardiol. Rev. 19(5), 19–26 (2023).
pubmed: 36959138
Berezin, A. E. Prognostication in different heart failure phenotypes: The role of circulating biomarkers. J. Circ. Biomark. 5, 6 (2016).
pubmed: 28936254
pmcid: 5548324
doi: 10.5772/62797
AbouEzzeddine, O. F. et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure). JACC Heart. Fail. 3(3), 245–252 (2015).
pubmed: 25742762
pmcid: 4369675
doi: 10.1016/j.jchf.2014.10.009
de Boer, R. A. et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 272(1), 55–64 (2012).
pubmed: 22026577
doi: 10.1111/j.1365-2796.2011.02476.x
Wesseling, M., de Poel, J. H. C. & de Jager, S. C. A. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Fail. 7(4), 1488–1501 (2020).
pubmed: 32424982
pmcid: 7373942
doi: 10.1002/ehf2.12728
Pahnke, A. et al. The role of Wnt regulation in heart development, cardiac repair and disease: A tissue engineering perspective. Biochem. Biophys. Res. Commun. 473(3), 698–703 (2016).
pubmed: 26626076
doi: 10.1016/j.bbrc.2015.11.060
Algul, S. et al. EGFR/IGF1R signaling modulates relaxation in hypertrophic cardiomyopathy. Circ. Res. 133(5), 387–399 (2023).
pubmed: 37477020
doi: 10.1161/CIRCRESAHA.122.322133
Arechederra, M. et al. Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. Biochim. Biophys. Acta. 1832(12), 2204–2215 (2013).
pubmed: 23994610
doi: 10.1016/j.bbadis.2013.08.008
Penna, C. et al. The inflammatory cytokine IL-3 hampers cardioprotection mediated by endothelial cell-derived extracellular vesicles possibly via their protein cargo. Cells. 10(1), 1–13 (2020).
doi: 10.3390/cells10010013
Poetsch, M. S., Strano, A. & Guan, K. Role of leptin in cardiovascular diseases. Front. Endocrinol. 11, 354 (2020).
doi: 10.3389/fendo.2020.00354
Braile, M. et al. VEGF-A in cardiomyocytes and heart diseases. Int. J. Mol. Sci. 21(15), 5294 (2020).
pubmed: 32722551
pmcid: 7432634
doi: 10.3390/ijms21155294
Obokata, M. et al. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur. Heart J. 40(45), 3707–3717 (2019).
pubmed: 31513270
pmcid: 7963136
doi: 10.1093/eurheartj/ehz626
Gallego, N. et al. Expanding the evidence of a semi-dominant inheritance in GDF2 associated with pulmonary arterial hypertension. Cells. 10(11), 3178 (2021).
pubmed: 34831401
pmcid: 8624726
doi: 10.3390/cells10113178
Zhang, Z., Warner, K. A., Mantesso, A. & Nor, J. E. PDGF-BB signaling via PDGFR-beta regulates the maturation of blood vessels generated upon vasculogenic differentiation of dental pulp stem cells. Front. Cell Dev. Biol. 10, 977725 (2022).
pubmed: 36340037
pmcid: 9627550
doi: 10.3389/fcell.2022.977725
Kilian, L. S., Voran, J., Frank, D. & Rangrez, A. Y. RhoA: A dubious molecule in cardiac pathophysiology. J. Biomed. Sci. 28(1), 33 (2021).
pubmed: 33906663
pmcid: 8080415
doi: 10.1186/s12929-021-00730-w
Harris, I. S. et al. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 110(6), 718–723 (2004).
pubmed: 15289381
doi: 10.1161/01.CIR.0000138190.50127.6A
de Bakker, M. et al. Sex-specific cardiovascular protein levels and their link with clinical outcome in heart failure. ESC Heart Fail. 11(1), 594–600 (2024).
pubmed: 38009274
doi: 10.1002/ehf2.14578
Kessler, E. L., Rivaud, M. R., Vos, M. A. & van Veen, T. A. B. Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol. Sex Differ. 10(1), 7 (2019).
pubmed: 30717770
pmcid: 6360698
doi: 10.1186/s13293-019-0223-0
Beale, A. L., Meyer, P., Marwick, T. H., Lam, C. S. P. & Kaye, D. M. Sex differences in cardiovascular pathophysiology: Why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 138(2), 198–205 (2018).
pubmed: 29986961
doi: 10.1161/CIRCULATIONAHA.118.034271
Candia, J. et al. Assessment of variability in the SOMAscan assay. Sci. Rep. 7(1), 14248 (2017).
pubmed: 29079756
pmcid: 5660188
doi: 10.1038/s41598-017-14755-5
Brankovic, M. et al. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney Int. 93(4), 952–960 (2018).
pubmed: 29191357
doi: 10.1016/j.kint.2017.09.013
Valstar, G. B. et al. Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk for cardiovascular disease: Rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic. BMJ Open. 9(6), e028408 (2019).
pubmed: 31171553
pmcid: 6561429
doi: 10.1136/bmjopen-2018-028408
Klimczak-Tomaniak, D. et al. Dynamic personalized risk prediction in chronic heart failure patients: A longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). Sci. Rep. 12(1), 2795 (2022).
pubmed: 35181700
pmcid: 8857321
doi: 10.1038/s41598-022-06698-3
de Bakker, M. et al. Machine learning-based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure. Eur. Heart J. Digit. Health. 4(6), 444–454 (2023).
pubmed: 38045440
pmcid: 10689916
doi: 10.1093/ehjdh/ztad056
Petersen, T. B. et al. HFrEF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms. EBioMedicine. 93, 104655 (2023).
pubmed: 37327673
pmcid: 10279550
doi: 10.1016/j.ebiom.2023.104655
Henkens, M. et al. The HFA-PEFF score identifies “early-HFpEF” phenogroups associated with distinct biomarker profiles. ESC Heart Fail. 9(3), 2032–2036 (2022).
pubmed: 35301820
pmcid: 9065816
doi: 10.1002/ehf2.13861
van Ommen, A. M. et al. Plasma proteomic patterns show sex differences in early concentric left ventricular remodeling. Circ. Heart Fail. 16(7), e010255 (2023).
pubmed: 37381923
pmcid: 10348648